Gene modified cell transplantation for vascular regeneration.
Cell Transplantation is one of the powerful tools to ameliorate the capillary flow in ischemic condition. EPC (Endothelial Progenitor Cell) was identified in adult peripheral blood and thought to be a suitable candidate for cell transplantation. Also, gene therapy is already promising choice for enhancing angiogenic property. The combination of cell transplantation and gene therapy should be more effective way to regenerate vasculature in ischemic region. Recently, several research reports have come out regarding gene modified cell transplantation. We will mainly focus on the background of EPC, and then gene modified EPC findings in this review.
Murasawa
Satoshi
S
Group of Vascular Regeneration, Institute of Biomedical Research and Innovation/Stem Cell Translational Research Laboratory, RIKEN Kobe Institute Center for Developmental Biology, Kobe, Japan. s-murasawa@cdb.riken.go.jp
Asahara
Takayuki
T
D000818:Animals; D001808:Blood Vessels / Q000502:physiology*; D002196:Capillaries / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000637:transplantation*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007511:Ischemia / Q000503:physiopathology / Q000628:therapy; D051379:Mice; D018919:Neovascularization, Physiologic / Q000235:genetics*; D012038:Regeneration / Q000235:genetics*; D033581:Stem Cell Transplantation; D014652:Vascular Diseases; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000096:biosynthesis
D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1